SCAI

This channel contains news about the Society for Cardiac Angiography and Interventions (SCAI), including coverage of its annual meeting and links to recently released practice guidelines. SCAI is a leading resource in interventional cardiology and cath lab techniques and technologies. 
 

iFR reference numbers posted for new users in the cath lab at Northwestern Medicine's Central DuPage Hospital in Winfield, Ill.
News | FFR Technologies | July 26, 2018

July 26, 2018 — The Society of Cardiac Angiography and Interventions (SCAI) released a focused update expert...

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018

July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of...

Two versions of the Abiomed Impella percutaneous ventricular assist device being shown at ACC 2018. Impella is the only device currently cleared by the FDA for use in cardiogenic shock.

Two versions of the Abiomed Impella percutaneous ventricular assist device displayed at ACC 2018. Impella is the only device that currently has a FDA indication for use in cardiogenic shock. 

Feature | Hemodynamic Support Devices | July 08, 2018 | Emmanouil S. Brilakis, M.D., Ph.D., FSCAI and Srihari S. Naidu, M.D., FSCAI
Cardiogenic shock (CS) is a low-cardiac-output state resulting in life-threatening end-organ hypoperfusion and hypoxia...
First Results Reported from AVIATOR 2 Registry for AFib Patients Undergoing PCI.

Photo courtesy of the American Heart Association

News | Atrial Fibrillation | May 15, 2018

May 15, 2018 – Results of the AVIATOR 2 international registry data show a discrepancy between physician perception...

SCAI Releases Consensus Guidelines for Femoral-Popliteal Arterial Interventional Device Selection
News | Peripheral Artery Disease (PAD) | May 15, 2018

May 15, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released new guidelines to...

SCAI Updates Consensus on Length of Stay for Percutaneous Coronary Intervention
News | Cath Lab | May 15, 2018

May 15, 2018 — Revised guidelines incorporating new data on discharge criteria for patients undergoing elective...

No Benefit Found Using Sodium Bicarbonate, Acetylcysteine to Prevent Kidney Injury, the result of the PRESERVE Trial to prevent acute kidney injury (AKI), presented at SCAI 2018.  #SCAI, #SCAI2018,
Feature | Cath Lab | May 15, 2018

May 15, 2018 – The large-scale, international randomized PRESERVE clinical trial found high-risk patients for renal...

Angiogram of a STEMI patient.
News | Cath Lab | May 15, 2018

May 15, 2018 — A contemporary, real-world analysis shows lower mortality rates when culprit-only intervention is...

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018

May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin...

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital.

A 3-D printed aortic root with an simulated implant of an Edwards Sapien TAVR valve. New clinical data points to length-of-stay as a new predictor of outcomes in TAVR patients. Image from Henry Ford Hospital. 

Feature | Heart Valve Technology | May 14, 2018

May 14, 2018 – A new study finds patients who stay in the hospital for more than 72 hours when undergoing trans-...

The Medtronic Endeavor drug-eluting stent was used in the PERSPECTIVE trial to test its durability in chronic total occlusions (CTOs). #SCAI, #SCAI2018

The Medtronic Endeavor drug-eluting stent was used in the PERSPECTIVE trial to test its durability in chronic total occlusions (CTOs).

News | Chronic Total Occlusion (CTO) | May 14, 2018

May 14, 2018 – One-year outcomes of patients undergoing chronic total occlusion (CTO) percutaneous coronary...

SCAI Launches Diagnosis and Treatment Toolkit for Peripheral Artery Disease
News | Peripheral Artery Disease (PAD) | May 14, 2018

May 14, 2018 — The Society for Cardiovascular Angiography and Interventions (SCAI) announced the launch of the...

PROGRESS-CTO flow chart for the hybrid algorithm. #SCAI, #SCAI2018
News | Chronic Total Occlusion (CTO) | May 14, 2018

May 14, 2018 — A significant update to the PROGRESS-CTO (PROspective Global Registry for the Study of Chronic Total...

Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018

May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients...

Richard Schatz, M.D., (center) is research director of cardiovascular interventions at the Heart, Lung, and Vascular Center at Scripps Clinic, speaking at a SCAI session on collaboration with industry to bring new device technologies to market. He is best known as the co-inventor of the first coronary stent, the Palmaz-Schatz stent. Left is Ziyad Hijazi, M.D., MPH, director of the Sidra Cardiac Program. #SCAI, #SCAI2018

Richard Schatz, M.D., (center) research director of cardiovascular interventions at the Heart, Lung, and Vascular Center at Scripps Clinic, speaking at a 2018 SCAI session on collaboration with industry to bring new device technologies to market. He is best known as the co-inventor of the first coronary stent, the Palmaz-Schatz stent. Left is Ziyad Hijazi, M.D., MPH, director of the Sidra Cardiac Program, Sidra Medical and Research Center, Doha, Qatar, who has been active in new device technologies for structural heart disease.

Feature | SCAI | May 14, 2018

Here is an aggregation of all the news and late-breaking studies presented at the 2018...

Overlay Init